Extract from M&A Insights

The below story was originally featured in our daily M&A Insights Newsletter. Selected stories, including this one, are posted to our website with some weeks of delay.
EQT-owned Karo Intressenter bids SEK 6bn for Karo Pharma
October 30, 2018

EQT's portfolio company Karo Intressenter has placed a public bid for all outstanding shares in Karo Pharma at SEK 5.97bn. Karo Pharma is a specialty pharmaceutical company which develops and markets products for pharmacies and the health care sector. With EBITDA of SEK 142m in 2017, the bid value corresponds to an EV/EBITDA of 46.3x. Earlier in 2018, Karo acquired a smaller product portfolio from LEO Pharma.

ⓘ This story was originally featured in our daily M&A Insights newsletter.
Our insights have been covered by: